希少バイオマーカー検体の収集と安定化市場規模、シェア、動向分析レポート：バイオマーカー別、最終用途別、地域別、セグメント予測、2025年～2030年

希少バイオマーカー検体の収集と安定化市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の希少バイオマーカー検体の収集・安定化市場規模は、2025～2030年にかけてCAGR 14.4%で拡大し、2030年までに923億9,000万米ドルに達する見込みです。

循環型希少バイオマーカーの潜在的用途の拡大は、これらの希少バイオマーカー検体の効果的で迅速な収集と安定化をサポートする製品の採用従事している技術開発者にとって有利な機会を生み出しています。さらに、がんのスクリーニング、診断、予後、治療モニタリングのためのリキッドバイオプシーの出現は、希少バイオマーカー検体の収集と安定化の市場における競合と能力を著しく強化し、収益成長の一助となっています。

循環型バイオマーカーは、価値の高い治療デリバリーシステムとして、また潜在的な診断薬としての可能性があることから、研究者はより高感度で迅速かつ柔軟な分析ツールを採用しつつあります。主要企業は、研究の可能性を拡大するために、これらの希少なバイオマーカー検体の収集と安定化のための新しい技術と製品を開発しています。相当数の利点があるにもかかわらず、臨床応用を克服するための課題はまだ残っています。

分離法の多くは特異性が高く高感度であるが、これまでのところ、臨床サンプルにおける製品の使用と有効性に関する十分なエビデンスがないです。これは、これらの方法間の分析感度の違いが非常に重要な役割を果たすため、希少バイオマーカー検体の臨床利用の妨げとなっています。しかし、これらの希少バイオマーカー検体の臨床的有用性に関する研究の増加は、臨床実施に関連する課題を効果的に解決することが期待されます。

希少バイオマーカー検体の収集と安定化市場レポートハイライト

• 循環無細胞DNA（ccfDNA）セグメントは2024年に36.0%で市場の最大シェアを占めました。
• 研究セグメントは2024年に74.1%の最高シェアを獲得。希少バイオマーカーセグメントの優位性は、その実施に焦点を当てた調査研究の増加によるところが大きいです。
• 診断セグメントは2030年までにCAGR 15.0%で拡大する見込みです。循環遊走細胞DNA（ccfDNA）、循環腫瘍細胞（CTC）、エクソソームなどの希少バイオマーカーは、主に研究環境で使用されてきたが、診断用途への応用がますます検討されています。
• 北米の希少バイオマーカーの検体の収集と安定化産業が2024年に52.1%のシェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 希少バイオマーカー検体の収集と安定化市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 希少バイオマーカー検体の収集と安定化市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 希少バイオマーカー検体の収集と安定化市場：バイオマーカー別、推定・動向分析

• バイオマーカー市場シェア、2024年と2030年
• セグメントダッシュボード
• バイオマーカーによる世界の希少バイオマーカー検体の収集と安定化市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 循環細胞遊離DNA（ccfDNA）
  • 循環腫瘍細胞（CTC）
  • エクソソーム/細胞外小胞
  • 循環細胞遊離RNA（ccfRNA）/miRNA

第5章 希少バイオマーカー検体の収集と安定化市場：最終用途別、推定・動向分析

• 最終用途市場シェア、2024年と2030年
• セグメントダッシュボード
• 最終用途による世界の希少バイオマーカー検体の収集と安定化市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 研究
  • 診断

第6章 希少バイオマーカー検体の収集と安定化市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • QIAGEN
  • Charles River Laboratories
  • F. Hoffmann-La Roche Ltd
  • Terumo Medical Corp
  • Thermofischer Scientific Inc
  • Eurofins Scientific
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc
  • Agilent Technologies, Inc
  • Merck KGaA
  • Siemens Healthcare GmbH

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 3 North America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 4 North America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
• Table 5 U.S. rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 6 U.S. rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 7 Canada rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 8 Canada rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 9 Mexico rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 10 Mexico rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 11 Europe rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 12 Europe rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 13 Europe rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
• Table 14 Germany rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 15 Germany rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 16 UK rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 17 UK rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 18 France rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 19 France rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 20 Italy rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 21 Italy rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 22 Spain rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 23 Spain rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 24 Sweden rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 25 Sweden rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 26 Norway rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 27 Norway rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 28 Denmark rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 29 Denmark rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
• Table 33 China rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 34 China rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 35 Japan rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 36 Japan rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 37 India rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 38 India rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 39 Australia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 40 Australia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 41 Thailand rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 42 Thailand rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 43 South Korea rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 44 South Korea rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 45 Latin America rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 46 Latin America rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 47 Latin America rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
• Table 48 Brazil rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 49 Brazil rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 50 Argentina rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 51 Argentina rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 52 Middle East and Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 53 Middle East and Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 54 Middle East and Africa rare biomarkers specimen collection and stabilization market, by country, 2018 - 2030 (USD Million)
• Table 55 South Africa rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 56 South Africa rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 59 UAE rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 60 UAE rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)
• Table 61 Kuwait rare biomarkers specimen collection and stabilization market, by biomarker, 2018 - 2030 (USD Million)
• Table 62 Kuwait rare biomarkers specimen collection and stabilization market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Rare Biomarkers Specimen Collection and Stabilization: Market outlook
• Fig. 9 rare biomarkers specimen collection and stabilization competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 rare biomarkers specimen collection and stabilization market driver impact
• Fig. 15 rare biomarkers specimen collection and stabilization market restraint impact
• Fig. 16 rare biomarkers specimen collection and stabilization market strategic initiatives analysis
• Fig. 17 rare biomarkers specimen collection and stabilization market: Biomarker movement analysis
• Fig. 18 rare biomarkers specimen collection and stabilization market: Biomarker outlook and key takeaways
• Fig. 19 rare biomarkers specimen collection and stabilization market: End Use movement analysis
• Fig. 20 rare biomarkers specimen collection and stabilization market: End Use outlook and key takeaways
• Fig. 21 Circulating Cell Free DNA (ccfDNA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Circulating Tumor Cells (CTCs) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Exosomes/Extracellular Vesicles market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Isolation kits & reagents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Serum/Plasma market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Nucleic acid & other biomolecules market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 RNA market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 DNA market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Research market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Screening market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Treatment monitoring market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Circulating Cell Free RNA (ccfRNA) / miRNA market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Blood collection tubes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 NIPT market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Research market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Transcriptomics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Pharmacogenomics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Transplant rejection market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Population screening market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Research market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Research labs/CROs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Prenatal clinics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Global rare biomarkers specimen collection and stabilization market: Regional movement analysis
• Fig. 65 Global rare biomarkers specimen collection and stabilization market: Regional outlook and key takeaways
• Fig. 66 North America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 U.S. rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Canada rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Europe rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 UK rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Germany rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 France rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Italy rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Spain rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Sweden rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Norway rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Denmark rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Asia Pacific rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Japan rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 China rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 India rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Australia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Thailand rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Korea rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Latin America rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Brazil rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Mexico rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Argentina rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Middle East and Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 South Africa rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 UAE rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Kuwait rare biomarkers specimen collection and stabilization market estimates and forecasts, 2018 - 2030 (USD Million)

Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends:

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.

Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights:

• The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
• The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
• The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
• North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Biomarker
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Biomarker outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Demand for Precision Medicine
    • 3.2.1.2. Advancements in Liquid Biopsy Technologies
    • 3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs
    • 3.2.2.2. Lack of Standardization
• 3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Estimates & Trend Analysis

• 4.1. Biomarker Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Circulating Cell Free DNA (ccfDNA)
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Circulating Tumor Cells (CTCs)
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.3. Exosomes/Extracellular Vesicles
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.2. By Product
      • 4.4.3.2.1. Isolation Kits & Reagents
        • 4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.2. Blood Collection Tubes
        • 4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.3. Systems
        • 4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.3. By Specimen Type
      • 4.4.3.3.1. Serum/Plasma
        • 4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.3.2. Others
        • 4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.4. By Nucleic Acid & Other Biomolecules
      • 4.4.3.4.1. RNA
        • 4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.2. DNA
        • 4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.3. Others
        • 4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.5. By Application
      • 4.4.3.5.1. NIPT
        • 4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.2. Oncology
      • 4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.1. Research
          • 4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.2. Diagnostics
          • 4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.3.5.3.2.2. Screening
    • 4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.3.2.3. Treatment Monitoring
    • 4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.4. Transcriptomics
        • 4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.5. Pharmacogenomics
        • 4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.6. Transplant Rejection
        • 4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.7. Population Screening
        • 4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.8. Cardiovascular Diseases
        • 4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.9. Other Applications
        • 4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.2. By Product
      • 4.4.4.2.1. Isolation Kits & Reagents
        • 4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.2.2. Blood Collection Tubes
        • 4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.3. By Application
      • 4.4.4.3.1. NIPT
        • 4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.2. Oncology
        • 4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.2. Research
          • 4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.3. Diagnostics
          • 4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.3. Transcriptomics
        • 4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.4. Pharmacogenomics
        • 4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.5. Transplant Rejection
        • 4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.6. Population Screening
        • 4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.7. Cardiovascular Diseases
        • 4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.8. Other Applications
        • 4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 5. Rare Biomarkers Specimen Collection and Stabilization Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Research
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.1.2. Research Labs/CROs
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Academic Institutes
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Diagnostics
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laboratories
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Hospitals
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.4. Prenatal clinics
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare Biomarkers Specimen Collection and Stabilization Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.1.5. )
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
  • 7.3.2. QIAGEN
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Charles River Laboratories
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. F. Hoffmann-La Roche Ltd
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Terumo Medical Corp
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Thermofischer Scientific Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Eurofins Scientific
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. PerkinElmer Inc
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Bio-Rad Laboratories, Inc
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Agilent Technologies, Inc
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Merck KGaA
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Siemens Healthcare GmbH
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives